<DOC>
	<DOCNO>NCT00549666</DOCNO>
	<brief_summary>A Phase 1 , drug , drug , interaction study Lurasidone HCl Ortho-tri cyclen</brief_summary>
	<brief_title>A Randomized , Placebo-Controlled , Two-Period , Crossover Study Evaluate Effect Lurasidone HCl Oral Contraceptive Pharmacokinetics Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>Subject female 18 40 year age Female subject reproductive potential demonstrate negative serum βhuman chorionic gonadotropin level consistent nongravid state screen visit Subject agrees take triphasic oral contraceptive , Ortho TriCyclen™ , throughout study . Subject history regular menstrual period substantial breakthrough bleed episode take Ortho TriCyclen™ . Subject body mass index &lt; 33 kg/m2 ( see Appendix 1 ) . Subject judge good health Subject must negative hepatiti HIV antibody screen . Subject clinically significant abnormality screen ECG . Subject history major GI abnormalities/peptic ulceration , hematological , genitourinary , cardiovascular ( include hypertension ) , renal , hepatic , pulmonary , psychiatric , endocrine ( include diabetes ) metabolic ( include glaucoma ) , neurologic cerebrovascular disease , history cancer . Subject systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg screening . Subject history chronic and/or active hepatic disease include elevation serum transaminase , hepatitis , biliary tract disease , history gastrointestinal surgery . Subject acute chronic medical psychiatric condition , opinion investigator , would limit patient safety confound result study . Subject ECG screening PR &gt; 240 msec ; QRS complex &gt; 120 msec ; QTcB &gt; 450 ; significant morphologic change nonspecific Twave change . Subject currently user illicit drug ( include `` recreational use '' ) include marijuana , recently use illicit drug , history drug alcohol dependence past year abuse within last 3 month . Subject consumes excessive amount alcohol Subject surgery within last 12 week , donate unit blood ( within 4 week ) , participate another clinical study within 30 day screen . Subjects hypertension , hyperlipidemia , diabetes also exclude . ( See package circular `` Contraindications '' ) Subject clinically significant abnormality screen clinical examination laboratory safety test Subject prolactin level 200 ng/mL screening .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>OC DDI</keyword>
	<keyword>lurasidone</keyword>
	<keyword>Latuda</keyword>
	<keyword>schizophenia</keyword>
</DOC>